» Articles » PMID: 31407030

Prevalence and Prognostic Value of Late Gadolinium Enhancement on CMR in Aortic Stenosis: Meta-analysis

Overview
Journal Eur Radiol
Specialty Radiology
Date 2019 Aug 14
PMID 31407030
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aim of this study was to investigate the prevalence and prognostic value of late gadolinium enhancement (LGE), as assessed by cardiovascular magnetic resonance (CMR) imaging, in patients with aortic stenosis.

Methods And Results: A systematic search of PubMed and EMBASE was performed, and observational cohort studies that analysed the prevalence of LGE and its relation to clinical outcomes in patients with aortic stenosis were included. Odds ratios were used to measure an effect of the presence of LGE on both all-cause and cardiovascular mortality. Nineteen studies were retrieved, accounting for 2032 patients (mean age 69.8 years, mean follow-up 2.8 years). We found that LGE is highly prevalent in aortic stenosis, affecting half of all patients (49.6%), with a non-infarct pattern being the most frequent type (63.6%). The estimated extent of focal fibrosis, expressed in % of LV mass, was equal to 3.83 (95% CI [2.14, 5.52], p < 0.0001). The meta-analysis showed that the presence of LGE was associated with increased all-cause (pooled OR [95% CI] = 3.26 [1.72, 6.18], p = 0.0003) and cardiovascular mortality (pooled OR [95% CI] = 2.89 [1.90, 4.38], p < 0.0001).

Conclusions: LGE by CMR is highly prevalent in aortic stenosis patients and exhibits a substantial value in all-cause and cardiovascular mortality prediction. These results suggest a potential role of LGE in aortic stenosis patient risk stratification.

Key Points: • Up to the half of aortic stenosis patients are affected by myocardial focal fibrosis. • Sixty-four percent of focal fibrosis detected by LGE-CMR is non-infarct type. • The presence of focal fibrosis triples all-cause and cardiovascular mortality.

Citing Articles

Cardiac Magnetic Resonance for Structural Aortic Valve Stenosis Procedures.

Ferrandez-Escarabajal M, Hadley M, Sanz J J Clin Med. 2024; 13(17).

PMID: 39274397 PMC: 11396107. DOI: 10.3390/jcm13175184.


Myocardial fibrosis associates with lupus anticoagulant in patients with systemic lupus erythematosus.

Myhr K, Zinglersen A, Pecini R, Jacobsen S Int J Cardiovasc Imaging. 2023; 40(1):127-137.

PMID: 37814154 PMC: 10774215. DOI: 10.1007/s10554-023-02970-3.


Is myocardial fibrosis appropriately assessed by calibrated and 2D strain derived integrated backscatter?.

Lima M, Abecasis J, Reis Santos R, Maltes S, Lopes P, Ferreira A Cardiovasc Ultrasound. 2023; 21(1):14.

PMID: 37568167 PMC: 10422833. DOI: 10.1186/s12947-023-00311-x.


Pathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis.

Shah S, Shah J, Lakey S, Garg P, Ripley D Open Heart. 2023; 10(1).

PMID: 36963766 PMC: 10040005. DOI: 10.1136/openhrt-2022-002244.


Functional and structural reverse myocardial remodeling following transcatheter aortic valve replacement: a prospective cardiovascular magnetic resonance study.

Lange T, Backhaus S, Beuthner B, Topci R, Rigorth K, Kowallick J J Cardiovasc Magn Reson. 2022; 24(1):45.

PMID: 35897100 PMC: 9331125. DOI: 10.1186/s12968-022-00874-0.


References
1.
Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V . Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003; 107(7):984-91. DOI: 10.1161/01.cir.0000051865.66123.b7. View